文献速递基础与转化研究新药、器械与细胞基因治疗研发组学、生物样本库与精准医学

靶表位单氨基酸变异可导致抗体类治疗耐药

Single-amino acid variants in target epitopes can confer resistance to antibody-based therapies.
PubMed 文献 · Sci Transl Med · 2025-12-17

研究分析了已批准及在研治疗性单抗的抗原识别受天然单核苷酸变异影响,几乎每种抗体均存在界面区蛋白变异,部分预测破坏结合;对四种抗原的实验验证显示部分变异完全丧失结合,如携带HER-2 P594H变异的乳腺癌细胞系对高效抗体偶联药物完全耐药。

要点

  • 几乎每种分析的治疗性单抗均存在位于或邻近抗体-抗原界面的蛋白变异,部分预测破坏抗原识别。
  • 实验验证四种抗原的选定变异,部分病例显示抗体结合完全丧失。
  • 过表达HER-2并携带HER-2 P594H变异的乳腺癌细胞系对高效临床抗体偶联药物完全耐药。

核心结论

  • 天然变异可赋予抗体类治疗原发耐药,对治疗结局、患者管理和安全性有重要意义,尤其对于抗体偶联药物等强效治疗模式。

研究设计与样本

  • 研究分析了已批准和在临床开发中的治疗性单克隆抗体,考察天然单核苷酸变异对抗原识别的影响。

主要发现

  • 几乎每种分析的抗体均鉴定出位于或邻近抗体-抗原界面的蛋白变异,其中一部分预测会破坏抗原识别。
  • 实验研究证实了四种不同抗原的选定变异的影响,部分病例显示抗体结合完全丧失。
  • 过表达人表皮生长因子受体2(HER-2)但经工程化携带HER-2 P594H变异的人乳腺癌细胞系,即使对高效临床抗体偶联药物也完全抵抗杀伤。
  • 个体耐药相关变异虽全球罕见,但在特定人群中富集。

临床怎么用

  • 作者认为,在药物开发和临床决策中应考虑遗传多样性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal antibodies have transformed the therapeutic landscape across oncology, immunology, and infectious diseases by enabling high-affinity, antigen-specific targeting to neutralize soluble molecules, block cellular interactions, or deplete cells. Although high specificity is critical for safety, it may confer an inherent susceptibility to even minor variations in the target epitope. Here, we investigated the impact of natural single-nucleotide variants on antigen recognition by therapeutic monoclonal antibodies, both approved and in clinical development. For almost every antibody analyzed, we identified protein variants in or near the antibody-antigen interface, a subset of which were predicted to disrupt antigen recognition. Experimental studies corroborated the impact of select variants for four different antigens, revealing complete loss of antibody binding in some cases. For example, a human breast cancer cell line overexpressing human epidermal growth factor receptor 2 (HER-2), but engineered to carry the HER-2P594H variant, was completely resistant to killing even by highly potent clinical antibody-drug conjugates. These findings suggest that natural variants can confer primary resistance to antibody-based therapies, with critical implications for treatment outcomes, patient management, and safety, particularly in the context of potent modalities such as antibody-drug conjugates. Individual resistance-associated variants, although globally rare, are enriched in specific populations, underscoring the importance of accounting for genetic diversity in both drug development and clinical decision-making.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Marone R, Asllanaj E, Capoferri G, et al. Single-amino acid variants in target epitopes can confer resistance to antibody-based therapies. Sci Transl Med. 2025. PMID: 41406240. doi:10.1126/scitranslmed.ady4877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。